Is This Innovative Cancer Research Biotech a Buy?
CytomX Therapeutics (NASDAQ: CTMX) is a small-cap biotech company with four cancer immunotherapy candidates in phase 1/2 clinical trials. The company's technology is based on its Probody therapies, which are infused through the bloodstream and designed to activate high levels of protein-breaking enzymes surrounding tumors to turn the disease against itself.
On May 14, abstracts pertaining to interim clinical data on two of the company's drugs, CX-072 and CX-2009, were published on the American Society of Clinical Oncology's 2020 Virtual Scientific Program. Investors who saw the reports didn't like them that much, and CytomX's share price was slashed by about 25% in a single day.
Image source: Getty Images.
Source Fool.com